item management s discussion and analysis of financial condition and results of operation 
results of operation the following table sets forth  for the three most recent fiscal years  the percentage relationship to net sales of principal items in the company s consolidated statements of income fiscal year ended june  net sales cost of goods sold gross profit selling expenses general and administrative expenses research and development expenses litigation recovery settlement expenses total operating expenses income from operations other income 

income before minority interest and income taxes minority interest in net income of consolidated subsidiaries 

income before provision for income taxes income tax provision net income 
the following discussion and analysis provides information which the company s management believes is relevant to an assessment and understanding of the company s results of operations and financial condition 
this discussion should be read in conjunction with the consolidated financial statements and notes thereto appearing elsewhere herein 
all of the company s sales to date have been derived from the sale of medical devices  which include manufacture and distribution of ultrasonic medical devices and laboratory and scientific products  which include  ultrasonic equipment for scientific and industrial purposes  ductless fume enclosures for filtration of gaseous emissions in laboratories and environmental control equipment for the abatement of air pollution 
fiscal years ended june  and net sales 
net sales of the company s medical devices and laboratory and scientific products increased  to  in fiscal from  in fiscal this difference in net sales is due to an increase in sales of medical devices of  to  in fiscal from  in fiscal this difference in net sales is also due to an increase in laboratory and scientific product sales of  to  in fiscal from  in fiscal the increase in sales of medical devices is due to an increase in sales of therapeutic medical devices of  and an increase of  in sales of diagnostic medical devices  both due to increased customer demand for several diagnostic and therapeutic medical products 
the increase in sales of diagnostic medical devices was not attributable to a single customer  distributor or any other specific factor 
the increase in sales of therapeutic medical devices was mostly attributable to an increase in sales to mentor of the lysonix device  the auto sonix device and accessories sold to uss and an increase of sales of the sonoblate of approximately   and  respectively 
the increase in sales of the sonoblate is due to both an increase in sales to focus as the manufacturer of the device  the sale of the device in europe by the company and revenue derived for fee per use or rental income 
sales are not recorded as revenue until the total earnings process is complete 
the increase in sales of laboratory and scientific products is due to an increase in labcaire sales of  and sales of ultrasonic laboratory products of  partially offset by a decrease in wet scrubber sales of  and a decrease in ductless fume enclosure sales of  the increase in labcaire sales is primarily due to the strengthening of the english pound of approximately  offset by a decrease in sales of the guardian endoscopic cleaning product of approximately  the increase in laboratory and scientific ultrasonic sales is due to an increase in customer demand for the ultrasonic sonicator product 
wet scrubber sales continue to be adversely affected by the downturn in the semi conductor market 
the decrease in fume enclosure sales is due to lower customer demand for several laboratory and scientific products and current economic conditions for such products 
export sales from the united states are remitted in us dollars and export sales for labcaire are remitted in english pounds 
during fiscal and fiscal  the company had foreign net sales of  and  respectively  representing and of net sales for such periods  respectively 
the increase in foreign sales in fiscal as compared to fiscal is substantially due to an increase in labcaire sales due to the strengthening of the english pound of approximately  as well as an increase in foreign diagnostic and therapeutic medical device sales as the company started to sell the ultrasonic neuroaspirator and the sonoblate to distributors in europe 
labcaire represented and of foreign net sales during fiscal and  respectively 
the remaining and represents net foreign sales remitted in us dollars during fiscal and  respectively 
approximately of the company s revenues for fiscal year were received in english pounds 
to the extent that the company s revenues are generated in english pounds  its operating results are translated for reporting purposes into us dollars using weighted average rates of and for the year ended june  and  respectively 
a strengthening of the english pound  in relation to the us dollar  will have the effect of increasing reported revenues and profits  while a weakening of the english pound will have the opposite effect 
since the company s operations in england generally set prices and bids for contracts in english pounds  a strengthening of the english pound  while increasing the value of its uk assets  might place the company at a pricing disadvantage in bidding for work from manufacturers based overseas 
the company collects its receivables in the currency the subsidiary resides in 
the company has not engaged in foreign currency hedging transactions  which include forward exchange agreements 
the company s revenues are generated from various geographic regions 
the following is an analysis of net sales by geographic region for the year ending june united states   canada   mexico   united kingdom   europe   asia   middle east   other   summarized financial information for each of the segments for the years ended june  and are as follows for the year ended june  laboratory and a medical scientific corporate and devices products unallocated total net sales    cost of goods sold    gross profit    selling expenses    research and development    total operating expenses     income from operations     a amount represents general and administrative expenses 
for the year ended june  laboratory and a medical scientific corporate and devices products unallocated total net sales    cost of goods sold    gross profit    selling expenses    research and development    total operating expenses     income from operations     a amount represents general and administrative and litigation settlement recovery expenses 
net sales for the three months ended june  were  compared to  for the three months ended june  this decrease of  for the three months ended june  is due to a decrease in sales of medical devices of  partially offset by an increase in laboratory and scientific products sales of  the decrease in sales of medical devices is due to a decrease in sales of diagnostic medical devices of  partially offset by an increase of  in sales of therapeutic medical devices 
the decrease in diagnostic medical devices is due to decreased customer demand for several diagnostic medical products 
the decrease in sales for diagnostic medical devices was not attributable to a single customer  distributor or any other specific factor 
the increase in sales for therapeutic medical devices was mostly attributable to an increase in sales to uss and mentor 
the increase in laboratory and scientific products sales is due to increased labcaire sales of  and an increase in ductless fume enclosure sales of  partially offset by a decrease in ultrasonic sales of  and a decrease in wet scrubber sales of  the increase in labcaire sales is primarily due to the strengthening of the english pound of approximately  partially offset by a decrease in sales of the guardian endoscopic cleaning product of approximately  the decrease in laboratory and scientific ultrasonic sales is due to an increase in customer demand for several ultrasonic products 
wet scrubber sales continue to be adversely affected by the downturn in the semi conductor market 
summarized financial information for each of the segments for the three months ended june  and are as follows for the three months ended june  laboratory and a medical scientific corporate and devices products unallocated total net sales    cost of goods sold    gross profit    selling expenses    research and development    total operating expenses     income from operations     a amount represents general and administrative expenses 
for the three months ended june  laboratory and a medical scientific corporate and devices products unallocated total net sales    cost of goods sold    gross profit    selling expenses    research and development    total operating expenses     income from operations     a amount represents general and administrative and litigation settlement recovery expenses 
gross profit 
gross profit increased to in fiscal from in fiscal gross profit for medical devices remained consistent with a gross profit of in fiscal and fiscal gross profit for laboratory and scientific products increased to in fiscal from in fiscal gross profit of medical devices was impacted by the favorable order mix for sales of therapeutic medical devices due to the fee per use revenue for the sonoblate  which carries higher margins 
this increase is offset by an unfavorable order mix of diagnostic medical devices  which traditionally carry lower margins 
the increase in gross profit for laboratory and scientific products is due to ultrasonic and ductless fume enclosure sales partially offset by lower gross profit for wet scrubber and labcaire sales 
the decrease in gross profit for wet scrubber sales is due to pricing pressures from competition 
gross profit increased to of sales in the three months ended june  from of sales in the three months ended june  gross profit for laboratory and scientific products increased to of sales in the three months ended june  from of sales in the three months ended june  gross profit for medical devices decreased from of sales in the three months ended june  to of sales in the three months ended june  the increase in gross profit for laboratory and scientific products was positively impacted by the favorable order mix for sales of ultrasonic products and wet scrubber sales partially offset by a decrease in gross profit of labcaire and ductless fume enclosure sales 
the decrease in gross profit for medical devices was impacted by the favorable order mix for sales of diagnostic medical devices offset by an unfavorable order mix of therapeutic medical devices 
the company manufactures and sells both medical devices and laboratory and scientific products with a wide range of product costs and gross margin dollars as a percentage of revenues 
selling expenses 
selling expenses increased  or to  of sales in fiscal from  of sales in fiscal medical devices selling expenses increased  due both to additional sales and marketing efforts for diagnostic medical devices and therapeutic medical devices 
the increase in therapeutic medical devices selling expenses of  is due to an increase in sales and marketing efforts relating to european distribution and the hiring of additional salesman for therapeutic medical devices 
laboratory and scientific products selling expenses decreased  predominantly due to a decrease in fume enclosure and wet scrubber commissions and ultrasonic marketing expenses offset by the strengthening of the english pound 
selling expenses increased  or to  of sales in the three months ended june  from  of sales in the three months ended june  medical devices selling expenses increased  due both to additional sales and marketing efforts for diagnostic medical devices and therapeutic medical devices 
the increase in therapeutic medical devices selling expenses of  is due to an increase in sales and marketing efforts relating to european distribution 
laboratory and scientific products selling expenses decreased  predominantly due to a decrease in fume enclosure  wet scrubber and ultrasonic commissions and marketing expenses offset by the strengthening of the english pound for labcaire selling expenses 
general and administrative expenses 
general and administrative expenses increased  or to  in fiscal from  in fiscal the increase is predominantly due to an increase in corporate general and administrative expenses relating to corporate insurance  information technology consulting  legal fees and other accrued corporate expenses partially offset by a decrease in bad debt expense due to payments received from focus 
the remaining increase is attributable to the strengthening of the english pound at labcaire 
general and administrative expenses decreased  or from  in the three months ended june  to  in the three months ended june  the decrease is predominantly due to a decrease in general and administrative expenses relating to severance costs offset in part by an increase in administrative staff  all attributable to labcaire  and a decrease in corporate expenses related to bad debt 
research and development expenses 
research and development expenses increased  or to  in fiscal from  in fiscal research and development expenses related to medical devices increased  and research and development expense related to laboratory and scientific products increased  research and development expenses related to medical devices increased predominantly due to efforts for therapeutic medical devices and an increase in amounts paid focus in fiscal for the development work performed for the company for the treatment of kidney and liver tumors utilizing high intensity focused ultrasound technology as compared to fiscal the increase in research and development expenses relating to laboratory and scientific products increased efforts in research and development efforts for labcaire and the strengthening of the english pound at labcaire 
research and development expenses increased  or for the three months ended june  from  to  for the three months ended june  research and development expenses related to medical devices increased  and research and development expense related to laboratory and scientific products increased  research and development expenses related to medical devices increased predominantly due to increased efforts for therapeutic medical devices and an increase in payments made to focus in three months ended june  for the development for the treatment of kidney and liver tumors utilizing high intensity focused ultrasound technology as compared to the three months ended june   as requested by the company 
the increase in laboratory and scientific products is due to increased research and development efforts for all laboratory and scientific products 
litigation recovery settlement expenses 
the company recorded a reversal of the litigation settlement for the fiscal year of  as compared to for the fiscal year the company recorded a reversal of the litigation settlement for the three months ended june  of  as compared to for the three months ended june  this reversal represents the sale of lysonix units by mentor that were received by mentor from lysonix under the settlement agreement with lysonix this inventory was previously reserved for in fiscal year june   as its saleability was uncertain 
other income expense 
other income was  in fiscal as compared to  in fiscal the increase of  for the fiscal year was primarily due to an increase in royalty income of  and a decrease in loss on impairment of investments of  the company received an additional royalty payment in the first quarter of fiscal of approximately  which was based upon a review of uss records that determined that royalties were due for prior years 
the review showed that uss owed and subsequently paid in the first quarter royalties due on a product that was not included in the original royalty computation 
the increase was also due to a decrease in loss on impairment of investments of hearing innovations of  the decrease in loss on impairment of hearing innovations is a direct result of a reduction of loans made to hearing innovations in the current year compared to loans made in the prior year 
other income was  in the three months ended june  as compared to  in the three months ended june  the increase of  for the three months ended june  was primarily due to a decrease in loss on impairment of investments of  the decrease in loss on impairment of hearing innovations is a direct result of a reduction of loans to hearing innovations in the current period compared to loans made in the prior period 
income taxes 
the effective tax rate is for the fiscal year ended june  as compared to an effective tax rate of for the fiscal year ended june  the current effective income tax rate of was impacted by no corresponding income tax benefit from the loss on impairment of hearing innovations of approximately  plus the standard consolidated tax rate of approximately 
the decrease in the effective tax rate for fiscal compared to fiscal is primarily due to the reduction in the impaired loans to hearing innovations 
the loss on impairment of hearing innovations is recorded with no corresponding tax benefit since these transactions are capital losses 
benefits for such losses are only received if the company has the ability to generate capital gains 
during the fourth quarter of fiscal  the company recorded a valuation allowance of  against the deferred tax asset related to the non cash compensation charge due to the recent decline in the company s stock price 
during the fourth quarter of fiscal  the company reduced the valuation allowance by  due to the recent increase in the company s stock price leaving a valuation allowance of  fiscal years ended june  and net sales 
net sales of the company s medical devices and laboratory and scientific products increased  to  in fiscal from  in fiscal this difference in net sales is due to an increase in sales of medical devices of  to  in fiscal from  in fiscal this increase is offset by lower laboratory and scientific product sales of  to  in fiscal from  in fiscal the increase in sales of medical devices is due to an increase in sales of diagnostic medical devices of  and an increase of  in sales of therapeutic medical devices  both due to increased customer demand for several diagnostic and therapeutic medical products 
the increase in sales for diagnostic medical devices was not attributable to a single customer  distributor or any other specific factor 
the increase in sales for therapeutic medical devices was mostly attributable to an increase in sales to uss of approximately  the remaining increase in therapeutic medical devices is due to increased demand for all products 
the decrease in laboratory and scientific products is due to decreased wet scrubber sales of  and a decrease in ductless fume enclosure sales of  primarily offset by an increase in labcaire sales of  and ultrasonic sales of  wet scrubber sales continue to be adversely affected by the downturn of the semi conductor market 
the decrease in fume enclosure sales is due to lower customer demand for several laboratory and scientific products and current economic conditions for such products 
the increase in labcaire sales is primarily due to the demand for the new guardian endoscopic cleaning product introduced in december export sales from the united states are remitted in us dollars and export sales for labcaire are remitted in british pounds 
during fiscal and fiscal  the company had foreign net sales of  and  respectively  representing and of net sales for such years  respectively 
the increase in foreign sales in fiscal as compared to fiscal is substantially due to an increase in labcaire sales of  labcaire represented and of foreign net sales during fiscal and fiscal  respectively 
approximately of the company s revenues in the year ended june  were received in english pounds currency 
to the extent that the company s revenues are generated in english pounds  its operating results are translated for reporting purposes into us dollars using weighted average rates of and for the year ended june  and  respectively 
a strengthening of the english pound  in relation to the us dollar  will have the effect of increasing reported revenues and profits  while a weakening of the english pound will have the opposite effect 
since the company s operations in england generally set prices and bids for contracts in english pounds  a strengthening of the english pound  while increasing the value of its uk assets  might place the company at a pricing disadvantage in bidding for work from manufacturers based overseas 
the company collects its receivables in the currency the subsidiary resides in 
the company has not engaged in foreign currency hedging transactions  which include forward exchange agreements 
the company s revenues are generated from various geographic regions 
the following is an analysis of net sales by geographic region for the year ending june united states   canada   mexico   united kingdom   europe   asia   middle east   other   summarized financial information for each of the segments for the years ended june  and are as follows for the year ended june  laboratory and a medical scientific corporate and devices products unallocated total net sales    cost of goods sold    gross profit    selling expenses    research and development    total operating expenses     income from operations     a amount represents general and administrative and litigation settlement recovery expenses 
for the year ended june  laboratory and a medical scientific corporate and devices products unallocated total net sales    cost of goods sold    gross profit    selling expenses    research and development    total operating expenses     income from operations     a amount represents general and administrative and litigation settlement recovery expenses 
net sales for the three months ended june  were  compared to  for the same period in fiscal this increase of  for the three months ended june  is due to an increase in sales of medical devices of  and an increase in laboratory and scientific products sales of  the increase in sales of medical devices is due to an increase in sales of diagnostic medical devices of  and an increase of  in sales of therapeutic medical devices  both due to increased customer demand for several diagnostic and therapeutic medical products 
the increase in sales for diagnostic medical devices was not attributable to a single customer  distributor or any other specific factor 
the increase in sales for therapeutic medical devices was mostly attributable to an increase in sales to uss of approximately  the increase in laboratory and scientific products sales is due to increased labcaire sales of  an increase in ultrasonic sales of  and an increase in wet scrubber sales of  primarily offset by a decrease in ductless fume enclosure sales of  the increase in labcaire sales is primarily due to the demand for the new guardian endoscopic cleaning product introduced in december the decrease in fume enclosure sales is due to lower customer demand for several laboratory and scientific products and current economic conditions for such products 
summarized financial information for each of the segments for the three months ended june  and are as follows for the three months ended june  laboratory and a medical scientific corporate and devices products unallocated total net sales    cost of goods sold    gross profit    selling expenses    research and development    total operating expenses     income from operations     for the three months ended june  laboratory and a medical scientific corporate and devices products unallocated total net sales    cost of goods sold    gross profit    selling expenses    research and development    total operating expenses    income from operations    a amount represents general and administrative and litigation settlement recovery expenses 
gross profit 
gross profit increased to in fiscal from in fiscal gross profit for medical devices increased to in fiscal from in fiscal gross profit for laboratory and scientific products decreased to in fiscal from in fiscal for fiscal year  gross profit was positively impacted by the favorable order mix for sales of therapeutic and diagnostic medical devices  mystaire scrubber sales had a significant increase in gross margin on all of its products  predominately due to the implementation of cost reduction efforts  and increased sales by labcaire  whose products traditionally carry lower gross margins 
gross profit increased to of sales in the three months ended june  from of sales in the three months ended june  gross profit for medical devices increased to of sales in the three months ended june  from of sales in the three months ended june  gross profit for laboratory and scientific products increased to of sales in the three months ended june  from of sales in the three months ended june  for the three months ended june   gross profit was positively impacted by the favorable order mix for sales of therapeutic and diagnostic medical devices  mystaire scrubber and fume enclosure sales had a significant increase in gross margin on all of its products  predominately due to the implementation of cost reduction efforts  the above were offset by an increase in sales by labcaire  whose products traditionally carry lower gross margins 
the company manufactures and sells both medical devices and laboratory and scientific products with a wide range of product costs and gross margin dollars as a percentage of revenues 
selling expenses 
selling expenses decreased  or to  of sales in fiscal from  of sales in fiscal medical device selling expenses increased  predominantly due to additional sales and marketing efforts of diagnostic medical devices 
laboratory and scientific selling expenses decreased  predominantly due to a decrease in fume enclosure and ultrasonic commissions and wet scrubber employees  due to the reduction of staff  marketing expenses and a decrease in labcaire sales personnel 
selling expenses decreased  or from  of sales in the three months ended june  to  of sales in the three months ended june  laboratory and scientific selling expenses decreased  predominantly due to decreased sales commissions for the wet scrubber products and a transfer of salaries of two labcaire employees to general and administrative expenses from selling expenses 
medical device selling expenses decreased  predominantly due to less sales and marketing efforts for therapeutic medical devices partially offset by additional sales and marketing efforts of diagnostic medical devices 
general and administrative expenses 
general and administrative expenses increased  or to  in fiscal from  in fiscal the increase is predominantly due to an increase in general and administrative expenses relating to severance costs and a transfer of two employees from selling expenses  all attributable to labcaire 
general and administrative expenses increased  or to  in the three months ended june  from  in the three months ended june  the increase is predominantly due to an increase in general and administrative expenses relating to severance costs and an increase in administrative staff  all attributable to labcaire 
research and development expenses 
research and development expenses increased  or 
to  in fiscal from  in fiscal research and development expenses related to medical devices decreased  and research and development expenses related to laboratory and scientific products increased  during fiscal year  the company funded  to focus to start research and development for the treatment of kidney and liver tumors utilizing high intensity focused ultrasound technology 
the company has the right to the technology if the company funds the development 
the company has exercised its right and started to fund the development of treatment of kidney and liver tumors 
during fiscal year  three customers reimbursed the company  in the amount of approximately  for certain product development expenditures incurred 
research and development expenses increased  or from  in the three months ended june  to  in the three months ended june  litigation recovery settlement expenses 
the company recorded a reversal of the litigation settlement for fiscal of  this reversal represents the following the sale of  of lysonix units by mentor that were received by mentor from lysonix in connection with inventory received under the settlement agreement with lysonix this inventory was previously reserved for in fiscal year june   as its saleability was uncertain and the reversal of an accrual of  for unpaid professional fees offset by an additional reserve for net assets received in connection with the settlement of  in fiscal year  the company recorded a reversal of the litigation settlement during the fourth quarter of fiscal of  the company recorded a litigation settlement charge of  during fiscal on april   the united states court of appeals for the federal circuit court issued a decision reversing in large part the decision of the trial court and granting the motion by mentor against mda  lysonix and the company for violation of mentor s us patent no 
 this patent covers mentor s license for ultrasonic assisted liposuction 
damages were awarded in favor of mentor of approximately  and  for interest 
the court also granted a permanent injunction enjoining further sales of the lysonix in the united states for the use of liposuction 
the court affirmed that the lower court did not have the ability to increase damages or award attorneys fees 
each defendant was jointly and severally liable as each defendant infringed proportionally 
mentor requested further relief in the trial court for additional damages 
accordingly  the company accrued an aggregate of  for damages  attorneys fees  interest and other costs during the third quarter and fourth quarter of fiscal year on april   the company resolved all issues related to the lawsuit brought by mentor 
under the terms of the settlement  the company paid mentor  for its share of the  settlement with mentor in exchange for a complete release from any monetary liability in connection with the lawsuit and judgment 
in connection with this litigation settlement  the company paid  and forgave accounts receivable of  in exchange for certain assets from mda lysonix  which the company expects to utilize in the future 
the net realizable value of those assets was  in addition  the company paid  of other accrued costs during fiscal in june  the company entered into a ten year worldwide  royalty free  distribution agreement with mentor for the sale  marketing and distribution of the lysonix soft tissue aspirator used for cosmetic surgery 
this agreement is a standard agreement for such distribution in that it specifies the product to be distributed  the terms of the agreement and the price to be paid for product covered under the agreement 
other income expense 
other income was  in fiscal as compared to  in fiscal other income was  in the three months ended june  as compared to  in the three months ended june  the increase of  for the fiscal year was primarily due to a decrease in loss on impairment of investments of focus of  and hearing innovations of  offset by lower royalty income of  and lower interest income of  the decrease in impairment of focus and hearing innovations is a direct result of current period loans to focus and hearing innovations being less than in the prior period 
royalties decreased since the first six months of fiscal included additional royalty payments of approximately  which was based upon an audit of uss records for prior years royalties 
the audit showed that uss owed and subsequently paid royalties due on prior year sales that were not included in the original royalty computation 
the decrease in interest income is due to less cash on hand and lower interest yields during the year as compared to the prior year 
income taxes 
the effective tax rate is for the fiscal year ended june  as compared to an effective tax rate of for the fiscal year ended june  the current effective tax rate of was impacted by no corresponding income tax benefit from the loss of the impairment of hearing innovations and focus by  plus the standard consolidated tax rate of approximately 
the loss on impairment of investments is recorded with no corresponding tax benefit since these transactions are capital losses 
the benefit for such losses are only utilized to the extent the company has the ability to generate capital gains 
during the first quarter of fiscal year  the company recorded a reduction of the valuation allowance applied against deferred tax assets in accordance with the provisions of sfas no 
accounting for income taxes which provided a one time income tax benefit of  the valuation allowance was established in fiscal year because the future tax benefit of certain below market stock option grants issued at that time could not be reasonably assured 
the company continually reviews the adequacy of the valuation allowance and recognized the income tax benefit during the quarter due to the reasonable expectation that such tax benefit will be realized due to the fiscal strength of the company 
during the fourth quarter of fiscal  the company recorded a valuation allowance of  against the deferred tax asset related to the non cash compensation charge due to the recent decline in the company s stock price 
with this valuation  management believes that it will generate taxable income sufficient to realize the tax benefit associated with future deductible temporary differences 
critical accounting policies general financial reporting release no 
 which was released by the securities and exchange commission in december  requires all companies to include a discussion of critical accounting policies or methods used in the preparation of the financial statements 
note of the notes to consolidated financial statements included in the company s annual report on form k for the year ended june  includes a summary of the company s significant accounting policies and methods used in the preparation of its financial statements 
the company s discussion and analysis of its financial condition and results of operations are based upon the company s financial statements  which have been prepared in accordance with accounting principles generally accepted in the united states 
the preparation of these financial statements requires the company to make estimates and judgments that affect the reported amounts of assets  liabilities  revenues and expenses 
on an on going basis  management evaluates its estimates and judgments  including those related to bad debts  inventories  goodwill  property  plant and equipment and income taxes 
management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances  the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources 
actual results may differ from these estimates under different assumptions or conditions 
the company considers certain accounting policies related to allowance for doubtful accounts  inventories  property  plant and equipment  goodwill and income taxes to be critical policies due to the estimation process involved in each 
allowance for doubtful accounts the company s policy is to review its customers financial condition prior to extending credit and  generally  collateral is not required 
the company utilizes letters of credit on foreign or export sales where appropriate 
inventories inventories are stated at the lower of cost first in  first out or market and consist of raw materials  work in process and finished goods 
management evaluates the need to record adjustments for impairments of inventory on a quarterly basis 
the company s policy is to assess the valuation of all inventories  including raw materials  work in process and finished goods 
property  plant and equipment property  plant and equipment are recorded at cost 
depreciation of property and equipment is provided using the straight line method over estimated useful lives ranging from to years 
depreciation of the labcaire building is provided using the straight line method over the estimated useful life of years 
leasehold improvements are amortized over the life of the lease or the useful life of the related asset  whichever is shorter 
the company s policy is to periodically evaluate the appropriateness of the lives assigned to property  plant and equipment and to make adjustments if necessary 
goodwill in july  the financial accounting standards board issued statement of financial accounting standards sfas no 
sfas and sfas sfas  business combinations and goodwill and other intangible assets  respectively 
sfas replaced accounting principles board apb opinion business combinations and requires the use of the purchase method for all business combinations initiated after june  sfas requires goodwill and intangible assets with indefinite useful lives to no longer be amortized  but instead be tested for impairment at least annually and whenever events or circumstances occur that indicate goodwill might be impaired 
with the adoption of sfas  as of july   the company reassessed the useful lives and residual values of all acquired intangible assets to make any necessary amortization period adjustments 
based on that assessment  only goodwill was determined to have an indefinite useful life and no adjustments were made to the amortization period or residual values of other intangible assets 
sfas provided a six month transitional period from the effective date of adoption for the company to perform an assessment of whether there is an indication that goodwill is impaired 
to the extent that an indication of impairment exists  the company must perform a second test to measure the amount of impairment 
the second test must be performed as soon as possible  but no later than the end of the fiscal year 
any impairment measured as of the date of adoption will be recognized as the cumulative effect of a change in accounting principle 
the company performed the first test and determined that there is no indication that the goodwill recorded is impaired and  therefore  the second test was not required 
the company also completed its annual goodwill impairment tests for fiscal in the fourth quarter 
there were no indications that goodwill recorded was impaired 
income taxes income taxes are accounted for in accordance with sfas no 
 accounting for income taxes 
under this method  deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases  operating loss and tax credit carryforwards 
deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled 
the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date 
stock based compensation the company accounts for its stock based compensation plans in accordance with apb opinion no 
 accounting for stock issued to employees apb and related interpretations 
under apb  because the exercise price of the company s employee stock options is generally set equal to the market price of the underlying stock on the date of grant  no compensation expense is recognized 
liquidity and capital resources working capital at june  and june  was  and  respectively 
for the fiscal year  cash provided by operations totaled  the increase in the cash provided by operations is due to an increase in net income  the collection of accounts receivable and royalties from the prior period and the increase of accounts payable and income tax payable partially offset by cash paid for inventory purchased for unshipped orders 
for the fiscal year  cash used in investing activities was  which primarily consisted of the purchase of property  plant and equipment during the regular course of business and loans made to hearing innovations 
for the fiscal year  cash provided by financing activities was  primarily consisting of proceeds from short term borrowings and the exercise of stock options partially offset by payments of short term borrowings and principal payments on capital lease obligations 
revolving credit facilities labcaire has a debt purchase agreement with lloyds tsb commercial finance 
the amount of this facility is approximately  pound  and bears interest at the bank s base rate and at june  and  respectively plus and a service charge of 
of sales invoice value and fluctuates based upon the outstanding united kingdom and european receivables 
the agreement expires on september  and covers all united kingdom and european sales 
at june   the balance outstanding under this overdraft facility was  and labcaire was in compliance with all financial covenants 
the company secured a  revolving credit facility with fleet bank on january  to support future working capital needs 
the revolving credit facility expires january  and has interest rate options ranging from libor plus per annum to prime rate plus 
per annum 
this facility is secured by the assets of the company 
this facility contains certain financial covenants  including requiring that the company maintain a ratio of debt to earnings before interest  depreciation  taxes and amortization of not greater than to  that the company maintain a working capital ratio of not less than to  and that the company maintain a tangible net worth of  the terms provide for the repayment of the debt in full on its maturity date 
on june   the company had  available on its line of credit 
the company is in compliance with all such covenants 
commitments the company has commitments under a revolving note payable  facility debt and capital and operating leases that will be funded from operating sources 
at june   the company s contractual cash obligations and commitments relating to the revolving note payable  facility debt and capital and operating leases are as follows less than after commitment year years years years total revolving note payable   facility debt      capital leases     operating leases     hearing innovations  inc during fiscal  the company entered into eight loan agreements whereby hearing innovations is required to pay the company an aggregate amount of  two of these notes aggregating  were due november  and are in default due to non payment 
the remaining six notes aggregating  were due june  and are in default due to non payment 
hearing innovations is currently negotiating with the company to extend the due dates of all its outstanding debt 
all notes bear interest at per annum 
the notes are secured by a lien on all of hearing innovations right  title and interest in accounts receivable  inventory  property  plant and equipment and processes of specified products whether now existing or arising after the date of these agreements 
the loan agreements contain warrants to acquire  shares of hearing innovations common stock  at the option of the company  at a cost of 
per share 
these warrants  which are deemed nominal in value  expire in october the company recorded an allowance against amounts loaned prior to april   which totaled  the related expense has been included in loss on impairment of hearing innovations in the accompanying consolidated statements of income 
the company believes the loans and related interest are impaired since the company does not anticipate that these loans will be paid in accordance with the contractual terms of the loan agreements and hearing innovations has no predictable cash flows from its product revenue 
the current ability of companies such as hearing innovations to access capital markets or incur third party debt is very limited and is likely to remain so for the foreseeable future 
in light of this fact  the company continues to review strategic options available to it and hearing innovations due to hearing innovations continuing need for financial support 
the company previously made the decision not to continue funding hearing innovations operations  however  the company loaned hearing innovations  to enable hearing innovations to reduce a substantial portion of their long term debt to certain third parties 
the company continues to believe that hearing innovations technology could provide a benefit to patients but the products require more improvement and market development 
all equity investments and debt in hearing innovations have been fully reserved and currently have a zero basis 
the current ability of companies such as hearing innovations to access capital markets or incur third party debt is very limited and is likely to remain so for the foreseeable future 
in light of this fact  hearing innovations suspended operations in april in connection with the adoption of fin  the company consolidated hearing innovations in its march  balance sheet as the entity was determined to be a vie and the company is its primary beneficiary 
the company elected to record the adoption of fin as a cumulative effect of an accounting change 
consolidating hearing innovations did not have a material impact on the company s consolidated results of operations or financial condition 
on july   hearing innovations sent all shareholders and creditors a plan for reorganization and disclosure statement 
the company committed to fund hearing innovations up to  for the reorganization plan 
hearing innovations plans to file for relief under chapter of the us bankruptcy code in september if the petition is approved  the company will own of the equity in hearing innovations 
off balance sheet arrangements the company has no off balance sheet arrangements that have or are reasonably likely to have a current or future effect on the company s financial condition  changes in financial condition  revenues or expenses  results of operations  liquidity  capital expenditures or capital resources that is material to the company 
other the company believes that its existing capital resources will enable it to maintain its current and planned operations for at least months from the date hereof due to increase in cash flow from operations 
the company expects future cash flow from operations to fund all ongoing cash flow needs 
in the opinion of management  inflation has not had a material effect on the operations of the company 
item a 
quantitative and qualitative disclosures about market risk market risk the principal market risks ie  the risk of loss arising from adverse changes in market rates and prices to which the company is exposed are interest rates on short term investments and foreign exchange rates  which generate translation gains and losses due to the english pound to us dollar conversion of labcaire 
foreign exchange rates approximately of the company s revenues in fiscal were received in english pounds currency 
to the extent that the company s revenues are generated in english pounds  its operating results are translated for reporting purposes into us dollars using weighted average rates of and for the fiscal year ended june  and  respectively 
a strengthening of the english pound  in relation to the us dollar  will have the effect of increasing its reported revenues and profits  while a weakening of the english pound will have the opposite effect 
since the company s operations in england generally sets prices and bids for contracts in english pounds  a strengthening of the english pound  while increasing the value of its uk assets  might place the company at a pricing disadvantage in bidding for work from manufacturers based overseas 
the company collects its receivables in the currency the subsidiary resides in 
the company has not engaged in foreign currency hedging transactions  which include forward exchange agreements 

